Metastatic prostate cancer in men initially treated with active surveillance presented at Annual Meeting of American Urological Association, New Orleans, Louisiana, May 15-19, 2015.

Journal of Urology

Volumn 195, Issue 5, 2016, Pages 1409-1414

  Yamamoto, Toshihiro ^b   Musunuru, Bindu ^a   Vesprini, Danny ^a   Zhang, Liying ^b   Ghanem, Gabriella ^a   Loblaw, Andrew ^a   Klotz, Laurence ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

neoplasm grading; neoplasm metastasis; prostatic neoplasms; risk factors; watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACTIVE SURVEILLANCE; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; COHORT ANALYSIS; FEASIBILITY STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; INTERMEDIATE RISK POPULATION; LOW RISK POPULATION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; SURVIVAL RATE; BIOPSY; BLOOD; DISEASE FREE SURVIVAL; INCIDENCE; METASTASIS; MULTIMODALITY CANCER THERAPY; ONTARIO; PATHOLOGY; PROCEDURES; PROSTATE; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SECONDARY; VERY ELDERLY; WATCHFUL WAITING;

AGED; AGED, 80 AND OVER; BIOPSY; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; NEOPLASM GRADING; NEOPLASM METASTASIS; ONTARIO; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; WATCHFUL WAITING;

EID: 84963650747     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2015.11.075     Document Type: Article

References (26)

1. T.J. Wilt, M.K. Brawer, K.M. Jones, and et al. Radical prostatectomy versus observation for localized prostate cancer N Engl J Med 367 2012 203
2. J. Hugosson, S. Carlsson, G. Aus, and et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial Lancet Oncol 11 2010 725
3. F.H. Schröder, J. Hugosson, S. Carlsson, and et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Eur Urol 62 2012 745
4. Y. Krakowsky, A. Loblaw, and L. Klotz Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics J Urol 184 2010 131
5. L. Klotz, D. Vesprini, P. Sethukavalan, and et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer J Clin Oncol 33 2015 272
6. L. Klotz, L. Zhang, A. Lam, and et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 2010 126
7. L. Zhang, A. Loblaw, and L. Klotz Modeling prostate specific antigen kinetics in patients on active surveillance J Urol 176 2006 1392
8. R. Etzioni, R. Gulati, A. Tsodikov, and et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines Cancer 118 2012 5955
9. A. Adamy, D.S. Yee, K. Matsushita, and et al. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer J Urol 185 2011 477
10. M.R. Cooperberg, J.E. Cowan, J.F. Hilton, and et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer J Clin Oncol 29 2011 228
11. J.J. Tosoian, B.J. Trock, P. Landis, and et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience J Clin Oncol 29 2011 2185
12. R.C.N. Van den Bergh, S. Roemeling, M.J. Roobol, and et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly Eur Urol 55 2009 1
13. M.S. Soloway, C.T. Soloway, A. Eldefrawy, and et al. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment Eur Urol 58 2010 831
14. E.D. Selvadurai, M. Singhera, K. Thomas, and et al. Medium-term outcomes of active surveillance for localised prostate cancer Eur Urol 64 2013 981
15. S.E. Eggener, P.T. Scardino, P.C. Walsh, and et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy J Urol 185 2011 869
16. H. Miyamoto, D.J. Hernandez, and J.I. Epstein A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy Hum Pathol 40 2009 1693
17. H.M. Ross, O.N. Kryvenko, J.E. Cowan, and et al. Do adenocarcinomas of the prostate with Gleason score (GS)≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol 36 2012 1346
18. B.J. Trock, C.C. Guo, M.L. Gonzalgo, and et al. Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system J Urol 182 2009 1364
19. J.I. Epstein, Z. Feng, B.J. Trock, and et al. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades Eur Urol 61 2012 1019
20. G. Gandaglia, G. Ploussard, H. Isbarn, and et al. What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series Urol Oncol Semin Orig Investig 33 2015 164.e1
21. C.C. Huang, M.X. Kong, M. Zhou, and et al. Gleason score 3 + 4=7 prostate cancer with minimal quantity of Gleason pattern 4 on needle biopsy is associated with low-risk tumor in radical prostatectomy specimen Am J Surg Pathol 11 2014 1
22. P. Toren, L. Wong, and N. Timilshina Active surveillance in patients with a PSA > 10 ng / mL Can Urol Assoc J 8 2014 702
23. F.A. Faisal, D. Sundi, P.M. Pierorazio, and et al. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature BJU Int 114 2014 E120
24. D.M. Moreira, L. Gerber, J.A. Thomas, and et al. Association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy Int J Urol 19 2012 741
25. A.J. Stephenson, A.G. Aprikian, L. Souhami, and et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer Urology 59 2002 652
26. A. Loblaw, L. Zhang, A. Lam, and et al. Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance J Urol 184 2010 1942